In this Oncology Brothers podcast episode, Naval Daver, MD, MD Anderson Cancer Center, Houston, Texas, discusses treatment strategies for both therapy‑related and de novo acute myeloid leukemia (AML), focusing on cases…
Tara Lin, MD, University of Kansas Medical Center, Kansas City, Kansas, discusses how she approaches choosing induction therapy for patients with treatment-related acute myeloid leukemia, emphasizing that fitness…
A preliminary clinical study looking at previously untreated metastatic melanoma showed promising results when treating with the combination of an IL-2 signaling agonist and nivolumab. Primary trial objectives…
Early data from the phase III CheckMate 067 trial, reported in September 2017, showed that patients with advanced melanoma treated with nivolumab, with or without ipilimumab, maintained their quality…
Authors of an article published in Clinical Genitourinary Cancer analyzed aspects of laparoscopic treatment of renal cell cancer during pregnancy. Led by Lucio Dell’Atti of the Department of…
CDC’s Dr. Manisha Patel describes clinical features of measles, how to diagnose it in a patient, and what to do if you suspect you have a case. [Includes…
Benjamin Prince, MD, MSCI, FAAAAI, allergist/immunologist at Nationwide Children’s Hospital in Columbus, Ohio, discusses when to consider starting IgG replacement therapy. IgG replacement therapy is pooled antibody from…
Benjamin Prince, MD, MSCI, FAAAAI, allergist/immunologist at Nationwide Children’s Hospital in Columbus, Ohio, discusses primary immunodeficiency diseases. Many patients have a genetic defect that results in part of…
A retrospective study’s multivariate analysis suggests that in the treatment of early invasive melanoma, the use of Mohs micrographic surgery is associated with better outcomes when compared with…
Despite an abundance of preclinical evidence supporting the treatment strategy of combining an IDO1 inhibitor with anti-PD-1/PD-L1 immunotherapy, the results of a recent clinical trial were unable to confirm…
In an observational comparative effectiveness study of targeted vs non-targeted therapy for metastatic renal cell carcinoma (mRCC), older patients saw modest survival advantages when treated with targeted therapies.…
